The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
Open accessAbstract
Human melanocytic nevi (moles) are benign lesions harboring activated oncogenes, including BRAF. Although this oncogene initially acts mitogenically, eventually, oncogene-induced senescence (OIS) ensues. Nevi can infrequently progress to melanomas, but the mechanistic relationship with OIS is unclear. We show here that PTEN depletion abrogates BRAF V600E-induced senescence in human fibroblasts and melanocytes. Correspondingly, in established murine BRAF V600E-driven nevi, acute shRNA-mediated depletion of PTEN prompted tumor progression. Furthermore, genetic analysis of laser-guided microdissected human contiguous nevus–melanoma specimens recurrently revealed identical mutations in BRAF or NRAS in adjacent benign and malignant melanocytes. The PI3K pathway was often activated through either decreased PTEN or increased AKT3 expression in melanomas relative to their adjacent nevi. Pharmacologic PI3K inhibition in melanoma cells suppressed proliferation and induced the senescence-associated tumor suppressor p15 INK4B. This treatment also eliminated subpopulations resistant to targeted BRAF V600E inhibition. Our findings suggest that a significant proportion of melanomas arise from nevi. Furthermore, these results demonstrate that PI3K pathway activation serves as a rate-limiting event in this setting, acting at least in part by abrogating OIS. The reactivation of senescence features and elimination of cells refractory to BRAF V600E inhibition by PI3K inhibition warrants further investigation into the therapeutic potential of simultaneously targeting these pathways in melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751 · cited 4×
“Other frequent genetic events include the loss of CDKN2A and ARF, amplification of CCND1 or CDK4 (Kamb et al. 1994; Nobori et al. 1994; Freeman et al. 2003; Curtin et al. 2005), and, as identified more recently, alterations in MMP8, GRM3, ERBB4, GRIN2A (Palavalli et al.”
BackgroundInfluentialDistinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Self-citationThe essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
Self-citationCrucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548
BrafV600E cooperates with Pten loss to induce metastatic melanoma
Dankort, D., Curley, D. P., Cartlidge, R. A., Nelson, B., Karnezis, A. N., Damsky Jr, W. E., You, M. J., DePinho, R. A., McMahon, M., & Bosenberg, M. (2009) · Nature Genetics · doi:10.1038/ng.356 · Cited by 1,189
Self-citationSenescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124 · cited 1×
“The factors and pathways identified in this way will likely be relevant for other tumor settings as well, as OIS is seen in many tissue types (Collado and Serrano 2010).”
BackgroundKarreth, F. A., Tay, Y., Perna, D., Ala, U., Tan, S. M., Rust, A. G., DeNicola, G., Webster, K. A., Weiss, D., Perez-Mancera, P. A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.032 · Cited by 653
Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice
Dhomen, N., Reis-Filho, J. S., da Rocha Dias, S., Hayward, R., Savage, K., Delmas, V., Larue, L., Pritchard, C., & Marais, R. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.022 · Cited by 594
Deregulated Akt3 Activity Promotes Development of Malignant Melanoma
Stahl, J. M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J. Q., Bosenberg, M. W., Kester, M., Sandirasegarane, L., & Robertson, G. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1399 · Cited by 594
Paraiso, K. H. T., Xiang, Y., Rebecca, V. W., Abel, E. V., Chen, Y. A., Munko, A. C., Wood, E., Fedorenko, I. V., Sondak, V. K., Anderson, A. R. A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2954 · Cited by 551
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset
Ceol, C. J., Houvras, Y., Jane-Valbuena, J., Bilodeau, S., Orlando, D. A., Battisti, V., Fritsch, L., Lin, W. M., Hollmann, T. J., Ferré, F., et al. (2011) · Nature · doi:10.1038/nature09806 · Cited by 542 · cited 1×
“Similarly, BRAFV600E-driven nevus models in zebrafish and mice allow for the identification of melanoma progression genes (Ceol et al. 2011; Karreth et al. 2011).”
BackgroundFreeman, D. J., Li, A. G., Wei, G., Li, H.-H., Kertesz, N., Lesche, R., Whale, A. D., Martinez-Diaz, H., Rozengurt, N., Cardiff, R. D., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00021-7 · Cited by 515
A negative feedback signaling network underlies oncogene-induced senescence
Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., & Cichowski, K. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.003 · Cited by 501
A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma
Yokoyama, S., Woods, S. L., Boyle, G. M., Aoude, L. G., MacGregor, S., Zismann, V., Gartside, M., Cust, A. E., Haq, R., Harland, M., et al. (2011) · Nature · doi:10.1038/nature10630 · Cited by 484
Dankort, D., Filenova, E., Collado, M., Serrano, M., Jones, K., & McMahon, M. (2007) · Genes & Development · doi:10.1101/gad.1516407 · Cited by 481
Self-citationDisruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
Guldberg, P., Straten, P. T., Birck, A., Ahrenkiel, V., Kirkin, A. F., & Zeuthen, J. (1997) · PubMed · Cited by 480
Exome sequencing identifies GRIN2A as frequently mutated in melanoma
Program, N. C. S., Wei, X., Walia, V., Lin, J. C., Teer, J. K., Prickett, T. D., Gartner, J., Davis, S., Stemke-Hale, K., Davies, M. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.810 · Cited by 471
Genetic Interaction Between NRAS and BRAF Mutations and PTEN/MMAC1 Inactivation in Melanoma
Tsao, H., Yang, G., Goel, V., Wu, H., & Haluska, F. G. (2004) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2004.22243.x · Cited by 467
Pro-senescence therapy for cancer treatment
Nardella, C., Clohessy, J. G., Alimonti, A., & Pandolfi, P. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3057 · Cited by 437
Cellular senescence in naevi and immortalisation in melanoma: a role for p16?
Gray-Schopfer, V. C., Cheong, S. C., Chong, H., Chow, J., Moss, T., Abdel-Malek, Z. A., Marais, R., Wynford-Thomas, D., & Bennett, D. C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603283 · Cited by 394
Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40535 · Cited by 374
Oncogene-Induced Cell Senescence — Halting on the Road to Cancer
Mooi, W. J., & Peeper, D. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062285 · Cited by 371
Self-citationAnalysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4
Program, N. C. S., Prickett, T. D., Agrawal, N. S., Wei, X., Yates, K. E., Lin, J. C., Wunderlich, J. R., Cronin, J. C., Cruz, P., Rosenberg, S. A., et al. (2009) · Nature Genetics · doi:10.1038/ng.438 · Cited by 352
Congenital Melanocytic Nevi Frequently Harbor NRAS Mutations but no BRAF Mutations
Bauer, J., Curtin, J. A., Pinkel, D., & Bastian, B. C. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700490 · Cited by 351
Denoyelle, C., Abou-Rjaily, G., Bezrookove, V., Verhaegen, M., Johnson, T. M., Fullen, D. R., Pointer, J. N., Gruber, S. B., Su, L. D., Nikiforov, M. A., et al. (2006) · Nature Cell Biology · doi:10.1038/ncb1471 · Cited by 349 · cited 4×
“2006), the available evidence supports a redundant role for p16 in senescence induced by mutant BRAF or NRAS in vitro (Michaloglou et al. 2005; Denoyelle et al. 2006; Haferkamp et al. 2009) and in vivo (Dhomen et al.”
BackgroundResultInfluentialForbes, S., Clements, J., Dawson, E., Bamford, S., Webb, T., Dogan, A., Flanagan, A., Teague, J., Wooster, R., Futreal, P. A., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602928 · Cited by 331
Dai, D. L., Martinka, M., & Li, G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.168 · Cited by 318
Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
Lin, W. M., Baker, A. C., Beroukhim, R., Winckler, W., Feng, W., Marmion, J. M., Laine, E., Greulich, H., Tseng, H., Gates, C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2615 · Cited by 297
N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
van 't Veer, L. J., Burgering, B. M., Versteeg, R., Boot, A. J., Ruiter, D. J., Osanto, S., Schrier, P. I., & Bos, J. L. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.7.3114 · Cited by 283
Epigenetic Silencing of the PTEN Gene in Melanoma
Mirmohammadsadegh, A., Marini, A., Nambiar, S., Hassan, M., Tannapfel, A., Ruzicka, T., & Hengge, U. R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0384 · Cited by 279
Epigenetic PTEN Silencing in Malignant Melanomas without PTEN Mutation
Zhou, X.-P., Gimm, O., Hampel, H., Niemann, T., Walker, M. J., & Eng, C. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64627-5 · Cited by 278
Brenner, A. J., Stampfer, M. R., & Aldaz, C. M. (1998) · Oncogene · doi:10.1038/sj.onc.1201919 · Cited by 272 · cited 2×
“Of note, similar to primary mammary epithelial cells (Brenner et al. 1998), primary melanocytes appear to be under selective pressure to lose p16 during in vitro propagation (Bennett 2003).”
BackgroundA novel AKT3 mutation in melanoma tumours and cell lines
Davies, M. A., Stemke-Hale, K., Tellez, C., Calderone, T. L., Deng, W., Prieto, V. G., Lazar, A. J. F., Gershenwald, J. E., & Mills, G. B. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604637 · Cited by 272
Dhawan, P., Singh, A. B., Ellis, D. L., & Richmond, A. J. (2002) · PubMed · Cited by 260
Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines.
Tsao, H., Zhang, X., Fowlkes, K., & Haluska, F. G. (2000) · PubMed · Cited by 234
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
Atefi, M., von Euw, E., Attar, N., Ng, C., Chu, C., Guo, D., Nazarian, R., Chmielowski, B., Glaspy, J. A., Comin-Anduix, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028973 · Cited by 227
Mutations of the BRAF Gene in Benign and Malignant Melanocytic Lesions
Yazdi, A. S., Palmedo, G., Flaig, M. J., Puchta, U., Reckwerth, A., Rütten, A., Mentzel, T., Hügel, H., Hantschke, M., Schmid-Wendtner, M.-H., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12559.x · Cited by 221
Kennedy, A. L., Morton, J. P., Manoharan, I., Nelson, D. M., Jamieson, N. B., Pawlikowski, J. S., McBryan, T., Doyle, B., McKay, C., Oien, K. A., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.02.020 · Cited by 213
Human melanocyte senescence and melanoma susceptibility genes
Bennett, D. C. (2003) · Oncogene · doi:10.1038/sj.onc.1206446 · Cited by 212
BRAF alterations are associated with complex mutational profiles in malignant melanoma
Daniotti, M., Oggionni, M., Ranzani, T., Vallacchi, V., Campi, V., Di Stasi, D., Torre, G. D., Perrone, F., Luoni, C., Suardi, S., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207780 · Cited by 210
Akt3 and Mutant V600EB-Raf Cooperate to Promote Early Melanoma Development
Cheung, M., Sharma, A., Madhunapantula, S. V., & Robertson, G. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5867 · Cited by 196
Akt3-Mediated Resistance to Apoptosis in B-RAF–Targeted Melanoma Cells
Shao, Y., & Aplin, A. E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4471 · Cited by 194
Whiteman, D. C., Zhou, X., Cummings, M. C., Pavey, S., Hayward, N. K., & Eng, C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10294 · Cited by 187
Analysis of N- and K-Ras Mutations in the Distinctive Tumor Progression Phases of Melanoma
Stas, M., Degreef, H., Demunter, A., De Wolf-Peeters, C., & van den Oord, J. J. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01601.x · Cited by 176
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice
Goel, V. K., Ibrahim, N., Jiang, G., Singhal, M., Fee, S., Flotte, T., Westmoreland, S., Haluska, F. S., Hinds, P. W., & Haluska, F. G. (2009) · Oncogene · doi:10.1038/onc.2009.95 · Cited by 165
Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma
Palavalli, L. H., Prickett, T. D., Wunderlich, J. R., Wei, X., Burrell, A. S., Porter-Gill, P., Davis, S., Wang, C., Cronin, J. C., Agrawal, N. S., et al. (2009) · Nature Genetics · doi:10.1038/ng.340 · Cited by 161
Prickett, T. D., Wei, X., Cárdenas-Navia, I., Teer, J. K., Lin, J., Walia, V., Gartner, J. J., Jiang, J., Cherukuri, P. F., Molinolo, A. A., et al. (2011) · Nature Genetics · doi:10.1038/ng.950 · Cited by 150
Mutation and Allelic Loss of the PTEN/MMAC1 gene in Primary and Metastatic Melanoma Biopsies
Birck, A., Ahrenkiel, V., Zeuthen, J., HOU-JENSEN, K., & Guldberg, P. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00877.x · Cited by 141
Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
Marone, R., Erhart, D., Mertz, A. C., Bohnacker, T., Schnell, C., Cmiljanović, V., Stauffer, F., García-Echeverría, C., Giese, B., Maira, S.-M., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0366 · Cited by 137
PTEN expression in normal skin, acquired melanocytic nevi, and cutaneous melanoma
Tsao, H., Mihm, M. C., & Sheehan, C. E. (2003) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(03)02473-3 · Cited by 133
Association of early malignant melanoma with nevocytic nevi
Stolz, W., Schmoeckel, C., Landthaler, M., & Braun‐Falco, O. (1989) · Cancer · doi:10.1002/1097-0142(19890201)63:3<550::aid-cncr2820630325>3.0.co;2-a · Cited by 115
Mutations of PIK3CA are rare in cutaneous melanoma
Omholt, K., Kröckel, D., Ringborg, U. K., & Hansson, J. (2006) · Melanoma Research · doi:10.1097/01.cmr.0000200488.77970.e3 · Cited by 114
Oncogene-Induced Senescence Does Not Require the p16INK4a or p14ARF Melanoma Tumor Suppressors
Haferkamp, S., Scurr, L. L., Becker, T. M., Frausto, M., Kefford, R. F., & Rizos, H. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.5 · Cited by 92
Dadzie, O. E., Yang, S., Emley, A., Keady, M., Bhawan, J., & Mahalingam, M. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08887.x · Cited by 45
Detection of a low frequency of activated ras genes in human melanomas using a tumorigenicity assay.
Raybaud, F., Noguchi, T., Marics, I., Adélaïde, J., Planche, J., Batoz, M., Aubert, C., de Lapeyrière, O., & Birnbaum, D. (1988) · PubMed · Cited by 37
Non-random spatial association of melanoma and naevi - a morphometric analysis
Smolle, J., Kaddu, S., & Kerl, H. (1999) · Melanoma Research · doi:10.1097/00008390-199908000-00011 · Cited by 27
Pavel, S., Smit, N. P. M., van der Meulen, H., Kolb, R. M., de Groot, A. J. L., van der Velden, P. A., Gruis, N. A., & Bergman, W. (2003) · Melanoma Research · doi:10.1097/00008390-200304000-00010 · Cited by 18
Cited by
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
Krauthammer, M., Kong, Y., Ha, B. H., Evans, P., Bacchiocchi, A., McCusker, J. P., Cheng, E., Davis, M. J., Goh, G., Choi, M., et al. (2012) · Nature Genetics · doi:10.1038/ng.2359 · Cited by 1,191
Forging a signature of in vivo senescence
Sharpless, N. E., & Sherr, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3960 · Cited by 1,104
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence
Kaplon, J., Zheng, L., Meissl, K., Chaneton, B., Selivanov, V. A., Mackay, G., van der Burg, S. H., Verdegaal, E. M. E., Cascante, M., Shlomi, T., et al. (2013) · Nature · doi:10.1038/nature12154 · Cited by 633
Self-citation
Metadata
- Authors
- Vredeveld, L. C. W., Possik, P. A., Smit, M. A., Meissl, K., Michaloglou, C., Horlings, H. M., Ajouaou, A., Kortman, P. C., Dankort, D., McMahon, M., Mooi, W. J., & Peeper, D. S.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2012-05-01
- Volume
- 26
- Issue
- 10
- Pages
- 1055-1069
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2131001269
- Cited by
- 262
- References
- 62
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.